BioFIND

1. Subjects must have bradykinesia and rigidity
2. Current or history of well documented resting tremor
3. Unilateral onset or persistent asymmetry, but not strictly unilateral at the time of Enrollment
4. A well established response to one or more dopaminergic agents and/or amantadine (the presence of levodopa induced dyskinesia is acceptable but not required)
5. Subject has progressive PD of 5 to 18 years of duration from the onset of symptoms
6. Male or female age of onset of PD 50 to 75 by history. Current ages would range from 55 to 93 based on #5 and #6 requirements
7. Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations
8. Willing and able to comply with scheduled visits, required study procedures and laboratory tests
    

1. Has other serious neurological disorders (clinically significant stroke, brain tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis, repeated head trauma)
2. Had early severe autonomic involvement. Symptomatic orthostatic, hypotension or urinary incontinence within one year of onset of disease symptom
3. Has a history of cancer (other than basal and squamous cell skin cancers), autoimmune disorder, liver disease, or hematologic disorders within the past 5 years
4. Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture
5. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia
6. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation
7. Use of investigational drugs or devices within 60 days prior to baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). 
8. Has lower body predominant symptoms
9. Has supra-nuclear gaze palsy, cerebellar abnormalities, corticospinal track signs
10. Has had brain surgery including pallidotomy, thalamotomy, subthalamotomy or deep brain stimulator (DBS) implantation
     

1. Male or female age 55 to 93 years or older at visit 1
2. Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations
3. Willing and able to comply with scheduled visits, required study procedures and laboratory tests
    

1. Family history of PD in first degree relatives
2. Has other serious neurological disorders (clinically significant stroke, brain tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis, repeated head trauma)
3. Has a history of cancer (other than basal and squamous cell skin cancers), autoimmune disorder, liver disease, or hematologic disorders within the past 5 years
4. Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture
5. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia
6. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation
7. Use of investigational drugs or devices within 60 days prior to baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10)
8. MoCA score <26

For further information regarding BioFIND inclusion/exclusion criteria, please contact: resources@michaeljfox.org